clinical practice guidelines
doi:10.1093/annonc/mds223
Non-epithelial ovarian cancer: ESMO Clinical
Practice Guidelines for diagnosis, treatment
and follow-up
N. Colombo1,5, M. Peiretti1, A. Garbi1, S. Carinelli2,4, C. Marini5 & C. Sessa3,4, on behalf of the
ESMO Guidelines Working Group*
Departments of 1Gynecologic Oncology; 2Pathology, European Institute of Oncology, Milan, Italy; 3Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;
4
Unit of New Drugs & Innovative Therapies, Department of Medical Oncology, San Raffaele Hospital, O.U. Medicine 1Q-A Fondazione Centro San Raffaele del Monte
Tabor, Milan, Italy; 5Department of Gynecologic Oncology, Universit Milano-Bicocca, Milan, Italy
incidence and epidemiology
Non-epithelial malignancies of the ovary account for 10% of
all ovarian cancers [1]. Germ cell tumors (GCTs) are
diagnosed principally in the rst two decades of life, whereas
sex cord-stromal tumors (SCSTs) are more common in adult
women (granulosa adult type has an average age at diagnosis
clinical practice
of 50 years, 90% of juvenile type occurs in pre-pubertal girls
guidelines
and Sertoli-Leydig occurs mainly in women younger than 40
years). The yearly adjusted incidence rate is 3.7/1 000 000 and
2.1/1 000 000 women for GCTs and SCSTs, respectively [2].
diagnosis and pathology/molecular
biology
The initial symptoms and signs of non-epithelial ovarian
tumors are usually a subacute pelvic pain and feeling of pelvic
pressure because of a pelvic mass and menstrual irregularities.
Diagnostic work-up should include pelvic ultrasound,
abdomino-pelvic computed tomography (CT-scan) and chest
X-ray. In young patients, serum human chorionic
gonadotropin (hCG), -fetoprotein (AFP) titers and lactate
dehydrogenase (LDH), complete blood count and liver and
renal function tests should be carried out. Inhibin is secreted
by granulosa cell tumors and could be a useful marker for this
disease [3]. In case of suspected gonadoblastomas, a
preoperative karyotype should be obtained on all pre-menarche
girls because of the propensity of these tumors to arise in
dysgenetic gonads [4].
Primary non-epithelial tumors of the ovary arising from the
cells specic to the ovary (germ cells, granulosa cells, theca
cells, stromal broblasts and steroid cells) are the most typical
*Correspondence to: ESMO Guidelines Working Group, ESMO Head Ofce,Via
L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland;
E-mail: clinicalguidelines@esmo.org
Approved by the ESMO Guidelines Working Group: October 2008, last update June
2012. This publication supersedes the previously published versionAnn Oncol 2010;
21 (Suppl 5): v31v36.
The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oup.com.
Annals of Oncology 23 (Supplement 7): vii20vii26, 2012
ovarian tumors; other gonadal tumors arise from non-specic
ovarian cells.
Classication of GCTs is well established (Table 1). These
tumors recapitulate the steps of development, from
undifferentiated germ cells to adult tissues. The primitive
GCTs, composed of undifferentiated germ cells and tumors
with extra-embryonic differentiation, are all malignant.
Teratomas are the most common GCTs; most of them are
composed of mature tissues and are benign (dermoid cysts). In
immature teratomas, embryonic tissues represent the
malignant potential and grading is prognostically relevant.
Other rare malignant GCTs represent a heterogeneous group
including somatic cancers arising in dermoids and some
monodermal teratomas [5].
Primitive GCTs and immature teratomas are chemosensitive
and susceptible to fertility-sparing surgery. Because of their
chemosensitivity and of the increasing adoption of fertility-
sparing surgery, the correct pathological diagnosis is essential.
Owing to the rarity of these ovarian tumors, a histological
second opinion of expert pathologist/s should always be
considered [level III]. Diagnosis can be made on conventional
histologic material; given the multiplicity of morphological
features, immunohistochemical markers (Table 2) and
chromosome 12p uorescence in situ hybridization can be
used to conrm the diagnosis in difcult cases. Salla4 and
OCT3/4 are widely used and more recently expression of SOX2
in embryonal carcinoma and primitive neuroectoderm of
teratoma has been recognized [6].
Sex cord-stromal and steroid cell tumors constitute a
heterogeneous group of tumors (Table 3) and vary in their
capacity to produce clinically signicant amounts of steroid
hormones. Those with sex cord elements are malignant, with
granulosa cell tumors being the most frequent histological type.
Neoplasms of pure ovarian stroma are mostly benign, >50%
of them being bromas. Unlike GCTs, SCSTs and steroid cell
tumors occur over a wide range of age and many are found in
peri and post-menopausal women; however, for specic tumor
types, the age range is often more limited. Since patients are
Annals of Oncology clinical practice guidelines
Table 1. Classication of germ cell tumor (GCTs) A subset of SCSTs is typically negative for FOXL2 on
immunostaining (retiform or poorly differentiated SLCTs), but
Primitive GCTs these tumors usually express a-inhibin and/or calretinin.
Dysgerminoma Among rare tumors including non-specic tumors of the
Yolk sac tumor ovary, the most frequent is small-cell carcinoma of
Embryonal carcinoma hypercalcemic type; it is the most common form of
Others undifferentiated carcinoma <40 years of age and the most
Mixed GCTs (specify components) common ovarian tumor associated with hypercalcemia. This
Biphasic or triphasic teratoma tumor is typically unilateral and should be differentiated from
Immature teratoma primitive GCTs and granulosa cell tumor.
Mature teratoma
Monodermal teratoma and somatic-type tumors associated with teratoma

staging and risk assessment

The staging system for non-epithelial ovarian cancers is
Table 2. Immunohistochemistry of primitive germ cell tumor (GCTs) generally adopted from that of epithelial ovarian cancer as
originally dened by the International Federation of Obstetrics
Salla4 OCT3/4 SOX2 and Gynecology. Surgical approach can be carried out through
Dys + + an open route or, in selected cases, by laparoscopy and
YST + robotics. A careful examination of the abdominal cavity is
EC + + + required. The staging procedure includes infracolic
omentectomy, biopsy of the diaphragmatic peritoneum,
Dys, Dysgerminoma; YST, yolk sac tumor; EC, embryonal carcinoma.
paracolic gutters, pelvic peritoneum and peritoneal washings.
There is no consensus about the role of systematic
Table 3. Classication of sex cord-stromal tumors (SCSTs) and steroid lymphadenectomy [9, 10].
cell tumors Node dissection should be carried out only in those cases
with evidence of nodal abnormality. For SCSTs, retroperitoneal
evaluation is not mandatory because of the very low incidence
Ovarian stromal tumors with sex cord elements
Adult granulosa cell tumor
of retroperitoneal metastases in the early stage [III, A]. An
Juvenile granulosa cell tumor
endometrial curettage must be carried out to rule out
Sertoli-Leydig cell tumors concomitant uterine cancers in patients with granulosa cell
Gynandroblastoma tumor. Sertoli-Leydig cells tumors are frequently low grade
Sex cord tumor with annular tubules malignancies, although occasionally a poorly differentiated
Others variety may behave more aggressively. These tumors typically
Pure stromal tumors produce androgens, and clinical virilization is noted in 7085%
Fibroma and thecoma, typical, cellular and mitotically active of patients.
Malignant tumors (brosarcoma) Unilateral salpingo-oophorectomy with preservation of the
Other ovarian stromal tumors contralateral ovary and the uterus is now considered the
Ovarian stromal tumor with minor sex cord elements adequate surgical treatment for patients with GCTs. This
Sclerosing stromal tumor surgical approach should be considered, even in the case of
Signet-ring stromal tumor advanced disease, because of the sensitivity of the tumor to
Microcystic stromal tumor chemotherapy. No systematic ovarian biopsy needs to be
Ovarian myxoma carried out when the contralateral ovary is macroscopically
Stromal-Leydig cell tumor normal [III, A]. Conservative surgery seems to be the
Steroid cell tumors appropriate approach in young patients also for stage I disease
Stromal luteoma, Leydig cell tumor SCSTs. In postmenopausal women and in patients with
Steroid cell tumor, not otherwise specied
advanced stage disease or with bilateral ovarian involvement,
abdominal hysterectomy and bilateral salpingo-oophorectomy
should be carried out with careful surgical staging.
frequently young and the majority of cases are unilateral, an Younger age and early-stage disease are the most important
accurate diagnosis is necessary for deciding the treatment and predictors for improved disease-specic survival for SCSTs;
the maintenance of fertility, wherever desirable. Combination studies with a long-term follow-up showed a 10-year survival
chemotherapy has only modestly improved the prognosis for rate difference between stage I to II and III to IV of 84% to
malignant diseases. In morphologically ambiguous cases, an 95%, 50% to 65% and 17% to 33%, respectively. Tumor size
immunopanel of a-inhibin, calretinin and FOXL2, together with has been proposed as another prognostic factor: in a multi-
mutational analysis of FOXL2 (402C-G) in a subset of cases, is institution series of 83 patients, Chan et al. showed that tumor
useful to conrm granulosa cell tumor of adult type. Recent size 10 cm contributed to decreased survival rates in both
reports demonstrated that mutation of FOXL2 (402C-G) is univariate and multivariate analyses [11, 12]. Stage is an
virtually present in all granulosa cell tumors of adult type [7, 8]. important prognostic factor for CGTs; however, because of the

Volume 23 | Supplement 7 | October 2012 doi:10.1093/annonc/mds223 | vii

clinical practice guidelines
sensitivity to chemotherapy, also advanced stage diseases can
have good prognosis.
treatment plan
early stages
GCTs. The majority of GCTs (60%70%) are diagnosed at an
early stage. Stage I patients have an excellent prognosis with
long-term disease free status in >90% of cases. Stage IA pure
dysgerminoma can be treated with surgery only. The
recurrence rate in this group of patients is relatively low (15%
25%) and they can be successfully treated at the time of relapse
with a high likelihood of cure (Figure 1).
Patients with Stage IA grade 1 immature teratoma do not
require further adjuvant chemotherapy after adequate surgical
staging [13]. The need for adjuvant chemotherapy in stage IA
G2-G3 and IB-IC is still controversial. Some published data
indicate that all grades of immature teratoma can be managed
with close surveillance after fertility-sparing surgery (III, A),
reserving chemotherapy for those cases in which post-surgery
recurrence is documented [14]. However, this policy is not
universally accepted.
Overall, the role of chemotherapy in stage IA to B non-
dysgerminomatous ovarian GCTs remains controversial: a
surveillance policy has been proposed by Charing Cross
Hospital and Mount Vernon Hospital groups in this subset of
patients [15]. Data from the English literature show that the
most used combination is bleomycin, etoposide and cisplatin
(BEP) [III, A].
Figure 1 Management of germ cell tumors (GCTs) of the ovary. X = suggested, * Properly surgical staged, (X) = suggested by some authors, = no therapy.
vii | Colombo et al.
Annals of Oncology
advanced stages and recurrences
GCTs. Fertility-sparing surgery should be considered also in
advanced stage disease with a cure rate of > 95%. Patients
should undergo debulking surgery to remove as much gross
tumor as possible, but without major extensive procedures
because of the high chemo-sensitivity of these tumors.
Platinum-based regimens have been the treatment of choice
over the past decade and the BEP regimen is the most widely
used platinum-based chemotherapy [16, 17]. The optimal
duration of therapy is still under debate; generally, three cycles
of BEP in completely resected disease and four to ve cycles
(bleomycin should be omitted to reduce the risk of lung
toxicity) for patients with macroscopic residual disease seem
appropriate [III, A]. Dysgerminomas are very sensitive to
radiotherapy; however, its use is limited to selected cases
because of the negative impact on fertility.
In patients, previously treated with platinum, who have
relapsed after a disease-free interval >6 months ( platinum-
sensitive relapse), ifosfamide/platinum (IP) with or without
paclitaxel (P; Taxol) should be considered as second-line
treatment. Further active chemotherapy regimens include:
vinblastineifosfamidecisplatinum (VeIP), cisplatin,
vinblastine and bleomycin (PVB). Patients resistant to a
cisplatin-based combination may receive vincristine
actinomycin Dcyclophosphamide (Cytoxan) [VAC] or
paclitaxelgemcitabine as salvage therapy [16].
The role of secondary cytoreductive surgery in patients with
recurrent or progressive ovarian GCTs remains controversial. It
may have some benets for a selected group of patients,
Volume 23 | Supplement 7 | October 2012
Annals of Oncology
particularly those with immature teratoma and a growing
teratoma syndrome.
The role of the new targeted agents in GCTs is yet to be
demonstrated. Target agents already investigated in testicular
tumors and of potential interest include tyrosine kinase
inhibitors (imatinib and sunitinib) and antiangiogenic agents
(bevacizumab).
Targeted agents either alone or in combination could
represent therapeutic options, but their role must be evaluated
in prospective studies [IIIV] [18].
treatment plan
early stages
SCSTs. The majority of SCSTs (60%95%) are diagnosed at
an early stage. Stage IA granulosa cell tumor disease has an
excellent prognosis after surgery alone and does not require
adjuvant therapy [4]. The selection of early-stage SCST
patients for any postoperative treatment is controversial. To
date, the relative benet of adjuvant chemotherapy has yet to
be demonstrated. Some authors would suggest adjuvant
therapy for stage IC patients with high mitotic index, in this
case platinum-based chemotherapy is the treatment of choice
[IIIII] (Figure 2).
The most commonly used regimen is the BEP combination
[19]. Alternative chemotherapy options include: etoposide plus
cisplatin; cyclophosphamide, doxorubicin (Adriamycin) and
cisplatin; paclitaxel and carboplatin; or platinum agent alone
[level IIIII] [20].
For Sertoli-Leydig cell tumors, postoperative adjuvant
chemotherapy should be considered for those patients with
stage I poorly differentiated or with heterologous elements
[level IIIII].
advanced stages and recurrences
SCSTs. Debulking surgery, whenever feasible, remains the
most effective treatment of metastatic or recurrent granulosa
cell tumors. Platinum-based chemotherapy is currently used
for patients with advanced stage SCSTs or recurrent disease,
with an overall response rate of 63%80% [21]. Unfortunately,
the majority of patients with advanced disease do not have
Figure 2 Management of sex cord stromal tumors (SCSTs) of the ovary. X = suggested, = no therapy.
Volume 23 | Supplement 7 | October 2012
clinical practice guidelines
durable remissions. BEP regimen for at least three cycles or
carboplatin/paclitaxel is currently recommended for adjuvant
postoperative chemotherapy and for patients with recurrent
SCSTs (III-A) [22].
Patients with steroid cell tumors, who have tumors that are
pleomorphic, have an increased mitotic count, are large or are
at an advanced stage should be treated with additional
postoperative platinum-based chemotherapy; either BEP if not
previously used or a taxaneplatinum combination may be the
most appropriate chemotherapeutic regimen [23].
The Gynecologic Oncology Group is currently conducting a
randomized phase II trial of BEP versus the combination of
paclitaxel and carboplatin for patients with newly diagnosed
and chemo-nave recurrent metastatic SCSTs of the ovary [24].
Alternative chemotherapy options include: PVB, etoposide
cisplatin, cyclophosphamidedoxorubicincisplatin, and VAC.
There are limited data regarding the utility of chemotherapy in
patients with persistent Sertoli-Leydig tumors, but responses in
patients with measurable disease have been reported [25].
Given the functional hormonal nature of granulosa cell tumors
which express steroid hormone receptors, there must be some
rationale for a hormone-based approach [26]. Response to
gonadotropin-releasing hormone agonists, tamoxifen,
progestins and aromatase inhibitors has been reported.
Antiangiogenic agents have also been investigated in patients
with recurrent adult granulosa cell tumor, due to the
overexpression of vascular endothelial growth factor and
vascularity of these tumors [27]. A recent experience at the
MD Anderson Cancer Center seems to conrm the potential
activity of bevacizumab even though this was in a very limited
number of patients. The Gynecologic Oncology Group is
currently conducting a phase II trial of bevacizumab for
women with recurrent sex cord-stromal ovarian tumors [III
IV].
response evaluation and follow-up
Serum tumor markers (hCG, AFP, LDH, CA 125 and inhibin)
can correlate with tumor response during chemotherapy. In
doi:10.1093/annonc/mds223 | vii
clinical practice guidelines
Table 4. Summary of recommendations
Diagnosis and pathology/molecular
biology
Staging and risk assessment
Early-stage GCTs: treatment plan
Advanced stage and recurrent GCTs:
treatment plan
Early-stage SCSTs: treatment plan
Advanced stage and recurrent SCSTs:
treatment plan
vii | Colombo et al.
Annals of Oncology
Diagnostic work-up should include pelvic ultrasound, abdomino-pelvic computed tomography (CT-scan) and
chest X-ray
In young patients, human chorionic gonadotropin (hCG), -fetoprotein (AFP) titers and lactate dehydrogenase
(LDH), complete blood count, and liver and renal function tests should be carried out
In case of suspected gonadoblastomas, a preoperative karyotype should be obtained on all pre-menarche girls
In primitive germ cell tumors (GCTs) and immature teratomas, histological second opinion by expert
pathologist(s) should always be considered. Diagnosis can be made on conventional histologic material
Neoplasms of pure ovarian stroma: in morphologically ambiguous cases, an immunopanel of a-inhibin,
calretinin and FOXL2, plus mutational analysis for FOXL2 (402C-G), is useful to conrm granulosa cell tumor
of adult type
Surgical approach can be carried out through open route or, in selected cases, by laparoscopy and robotics
A careful examination of the abdominal cavity is required
Staging procedure includes infracolic omentectomy, biopsy of the diaphragmatic peritoneum, paracolic gutters,
pelvic peritoneum and peritoneal washings
Node dissection should be carried out only in the cases with evidence of nodal abnormality
For SCSTs retroperitoneal evaluation is not mandatory
An endometrial curettage must be carried out to rule out concomitant uterine cancers in patients with GCTs
Unilateral salpingo-oophorectomy with preservation of the contralateral ovary and the uterus is considered an
adequate surgical treatment for patients with GCTs. This should be considered even in advanced disease
because of the sensitivity of the tumor to chemotherapy. No systematic ovarian biopsy is necessary when the
contralateral ovary is macroscopically normal
Conservative surgery seems to be the appropriate approach in young patients also for stage I disease SCSTs
In postmenopausal women and in patients with advanced stage disease or with bilateral ovarian involvement,
abdominal hysterectomy and bilateral salpingo-oophorectomy should be carried out with careful surgical staging
Stage IA pure dysgerminoma can be treated with surgery only
Patients with Stage IA grade 1 immature teratoma do not require further adjuvant chemotherapy after adequate
surgical staging (14)
The need for adjuvant chemotherapy in stage IA G2-G3 and IB-IC is still controversial. Some data indicate that
all grades of immature teratoma can be managed with close surveillance after fertility-sparing surgery, reserving
chemotherapy for cases in which post-surgery recurrence is documented
Patients should undergo debulking surgery to remove as much gross tumor as possible, but without major
extensive procedures
Platinum-based regimens are the treatment of choice with bleomycin, etoposide and cisplatin (BEP) regimen the
most widely used, generally, three cycles of BEP in completely resected disease and four to ve cycles
(bleomycin should be omitted to reduce the risk of lung toxicity) for patients with macroscopic residual disease
In patients, previously treated with platinum, relapsed after a disease-free interval >6 months (platinum-
sensitive relapse), combinations with platinum should be considered
Patients resistant to a cisplatin-based combination may receive VAC or paclitaxelgemcitabine as salvage therapy
Targeted agents either alone or in combination could represent therapeutic options, but their role must be
evaluated in prospective studies
Stage IA granulosa cell tumor disease has an excellent prognosis after surgery alone and does not require
adjuvant therapy. Some authors would suggest adjuvant therapy for stage IC patients with high mitotic index, in
this case platinum-based chemotherapy is the treatment of choice
BEP is the most commonly used regimen. Alternative chemotherapy options include: etoposide plus cisplatin;
cyclophosphamide, doxorubicin and cisplatin; paclitaxel and carboplatin; or platinum agent alone
Sertoli-Leydig cell tumors: postoperative adjuvant chemotherapy should be considered for patients with stage I
poorly differentiated or heterologous elements
Debulking surgery remains the most effective treatment of metastatic or recurrent granulosa cell tumor.
Platinum-based chemotherapy is currently used for patients with advanced stage SCSTs or recurrent disease
BEP regimen for 3 cycles or carboplatin/paclitaxel is recommended for adjuvant postoperative chemotherapy
and patients with recurrent SCSTs
Patients with steroid cell tumors, with tumors that are pleomorphic, have an increased mitotic count, are large,
or are at an advanced stage should be treated with additional postoperative platinum-based chemotherapy;
either BEP if not previously used or a taxaneplatinum combination
Response to gonadotropin-releasing hormone agonists, tamoxifen, progestins and aromatase inhibitors has been
reported
Volume 23 | Supplement 7 | October 2012
Annals of Oncology
Response evaluation and follow-up
clinical practice guidelines
Serum tumor markers (hCG, AFP, LDH, CA 125 and inhibin) can correlate with tumor response during
chemotherapy
A CTscan of the abdomen, pelvis and chest (in case of suspected lung metastases) and pelvic ultrasound are
the most common and useful imaging techniques to evaluate the response to chemotherapy
Follow-up visits must include history, physical examination with pelvic examination and tumor markers every 3
months for the rst 2 years, then every 6 months during the third, fourth and fth year or until progression
A pelvic ultrasound should be carried out every 6 months in those patients who have undergone fertility-
sparing surgery, whereas a CT-scan of the abdomen and pelvis is carried out according to clinical indication
PET-scan for tumor response evaluation or follow-up is not yet well established

particular, inhibin is secreted by granulosa cell tumors and is a
useful tumor marker that falls after tumor removal and is also
a marker for tumor recurrence. CA125 is not increased in
GCTs, but sometimes it is useful in detecting relapse in those
with values of AFP/BHCG within the normal range. CT-scan
of the abdomen, pelvis and chest (in case of suspected lung
metastases) and pelvic ultrasound are the most common and
useful imaging techniques used to evaluate the response to
chemotherapy in patients with measurable disease (Table 4).
Approximately 75% of GCT recurrences occur within the rst
year after initial treatment; the most common site is the
peritoneal cavity, more rarely retroperitoneal lymph nodes.
Conversely, the indolent nature of SCSTs with the tendency for
late recurrence (the median time to relapse is 4 to 6 years)
requires long-term follow-up. Several reports describe relapses
occurring >20 years (up to 37 years) after diagnosis. The
common sites of recurrence are the upper abdomen (55%70%)
and the pelvis (30%45%). Follow-up visits must include history,
physical examination with pelvic examination and tumor markers
every 3 months for the rst 2 years, then every 6 months during
the third, fourth and fth year or until progression. A pelvic
ultrasound should be carried out every 6 months in those
patients who have undergone fertility-sparing surgery, whereas a
CT-scan of the abdomen and pelvis is usually carried out
according to clinical indication. The use of PET-scan for tumor
response evaluation or follow-up is not yet well established.
conict of interest
The authors have reported no potential conicts of interest.
references
1. Smith HO, Berwick M, Verschraegen CF et al. Incidence and survival rates for
female malignant germ cell tumors. Obstet Gynecol 2006; 107(5): 10751085.
2. Parkinson CA, Hatcher HM, Ajithkumar TV. Management of malignant ovarian
germ cell tumors. Obstet Gynecol Surv 2011; 66(8): 507514.
3. Hildebrandt RH, Rouse RV, Longacre TA. Value of inhibin in the identication of
granulosa cell tumors of the ovary. Hum Pathol 1997; 28: 13871395.
4. Colombo N, Parma G, Zanagnolo V et al. Management of ovarian stromal cell
tumors. J Clin Oncol 2007; 25: 29442951.
5. Tavassoli FA, Deville P. Pathology and Genetics of Tumours of the Breast and
Female genital organs. Lyon, France: International Agency for Research on
Cancer 2003; 163179.
6. Schumer S, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003;
21(6): 11801189.
7. Al-Agha OM, Huwait HF, Chow C et al. FOXL2 is a sensitive and specic marker
for sex cord-stromal tumors of the ovary. Am J Surg Pathol 2011; 35:
484494.
8. Gopalan A, Dhall D, Olgac S et al. Testicular mixed germ cell tumors: a
morphological and immunohistochemical study using stem cell markers, OCT3/4,
SOX2 and GDF3, with emphasis on morphologically difcult-to-classify areas.
Mod Pathol 2009; 22: 10661074.
9. Mahdi H, Swensen RE, Hanna R. Prognostic impact of lymphadenectomy in
clinically early stage malignant germ cell tumour of the ovary. Br J Cancer 2011;
105(4): 493.
10. Brown J, Sood AK, Deavers MT et al. Patterns of metastasis in sex cord-stromal
tumors of the ovary: Can routine staging lymphadenectomy be omitted? Gynecol
Oncol 2009; 113(1): 8690.
11. Chan JK, Zhang M, Kaleb V et al. Prognostic factors responsible for survival in
sex cord stromal tumors of the ovarya multivariate analysis. Gynecol Oncol
2005; 96: 204209.
12. Zhang M, Cheung MK, Shin JY et al. Prognostic factors responsible for survival
in sex cord stromal tumors of the ovary: an analysis of 376 women. Gynecol
Oncol 2007; 104(2): 396400.
13. Mangili G, Scarfone G, Gadducci A et al. Is adjuvant chemotherapy indicated in
stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian
cancer (MITO-9). Gynecol Oncol 2010; 119(1): 4852.
14. Gershenson DM. Management of early ovarian cancer: germ cell and sex cord-
stromal tumors. Gynecol Oncol 1994; 55(3 Pt 2): S62S72.
15. Dark GG, Bower M, Newlands ES et al. Surveillance policy for stage I ovarian
germ cell tumors. J Clin Oncol 1997; 15(2): 620624.
16. Williams SD, Blessing JA, Hatch KD et al. Chemotherapy of advanced
dysgerminoma: trials of the Gynecologic Oncology Group. J Clin Oncol 1991; 9:
19501955.
17. Bajorin DF, Sarosdy MF, Pster GD et al. Randomized trial of etoposide and
cisplatin versus etoposide and carboplatin in patients with good-risk germ cell
tumors: a multi-institutional study. J Clin Oncol 1993;11: 598606.
18. Manchana T, Ittiwut C, Mutirangura A et al. Targeted therapies for rare
gynaecological cancers. Lancet Oncol 2010; 11(7): 685693.
19. Homesley HD, Bundy BN, Hurteau JA et al. Bleomycin, etoposide, and cisplatin
combination therapy of ovarian granulosa cell tumors and other stromal
malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 1999; 72:
131137.
20. Obata NH, Nakashima N, Kawai M et al. Gonadoblastoma with dysgerminoma in
one ovary and gonadoblastoma with dysgerminoma and yolk sac tumor in the
contralateral ovary in a girl with 46XX karyotype. Gynecol Oncol 1995; 58:
124128.
21. Wolf JK, Brown J. Management of stromal tumors of the ovary. ASCO 2008;
2008 Educational Book.
22. Pautier P, Gutierrez-Bonnaire M, Rey A et al. Combination of bleomycin,
etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell
tumors. Int J Gynecol Cancer 2008; 18: 446452.
23. Teoh D, Freedman R, Soliman PT. Nearly 30 years of treatment for recurrent
granulosa cell tumor of the ovary: a case report and review of the literature. Case
Rep Oncol 2010; 3: 1418.

Volume 23 | Supplement 7 | October 2012 doi:10.1093/annonc/mds223 | vii

clinical practice guidelines
24. Brown J, Shvartsman HS, Deavers MT et al. The activity of taxanes in
the treatment of sex cord-stromal ovarian tumors. J Clin Oncol 2004;
22: 3517.
25. Evans AT, Gaffey TA, Malkasian GD et al. Clinicopathologic review of
118 granulosa and 82 theca cells tumors. Obstet Gynecol 1980;
55: 231.
vii | Colombo et al.
Annals of Oncology
26. Hardy RD, Bell JG, Nicely CJ et al. Hormonal treatment of a recurrent granulosa
cell tumor of the ovary: case report and review of the literature. Gynecol Oncol
2005; 96: 865.
27. Tao X, Sood AK, Deavers MT et al. Anti-angiogenesis therapy with bevacizumab
for patients with ovarian granulosa cell tumors. Gynecol Oncol 2009; 114:
431436.
Volume 23 | Supplement 7 | October 2012